SurgMark GmbH today announced that the U.S. Food & Drug Administration (FDA) has issued a 510(k) premarket notification for its SchurSign® Tissue Marker. The soft, biomaterial based implant for tissue marking offers promising prospects for a new standard in breast cancer diagnostics and care.
Hamburg, 23.01.2024 – The 510(k) clearance of SchurSign® by the FDA is a significant step towards an effective and gentle option in breast cancer diagnostics and care that will soon be available to patients in the US. SurgMark's tissue marker shows consistently good visibility in all breast imaging modalities, especially in ultrasound. The product is based on chitosan, a naturally occurring polysaccharide. This biomaterial is tissue-friendly and flexible and causes significantly less foreign body reactions than conventional metal markers often do. Christine König, PhD, CEO of SurgMark, shares her excitement: "We believe our device will improve the quality of life for women in the US and soon around the world by providing them with a non-metallic product which, when in the body, is soft, therefore causing less pain or discomfort. Most importantly, SchurSign is easily visible by ultrasound and MRI. FDA clearance really marks a very significant milestone in our corporate development. It catapults us onto a new trajectory of our mission to improve breast cancer diagnostics and treatment for women around the world."
Next steps towards entering the US Market
With the clearance of the FDA’s 510(k) process SurgMark is accelerating the availability of SchurSign® to patients in the US. Together with its partners, the company is now preparing to conduct clinical studies in North America and Europe and is building its distribution network. Alpo Medizintechnik GmbH, a German contract manufacturer and SurgMark’s strategic partner, is the manufacturer of the marker and is involved in development and manufacture of a newly designed and more ergonomic inserter for SchurSign®.
In North America, the number of new cases of breast cancer is about 330,000 annually and rising, with an approximately 5-fold higher number of suspected cases. SchurSign® will be reimbursable through health insurance companies under the codes for breast biopsy procedures.
The results of clinical trials with SchurSign® in North America and Europe form the prerequisite for approval as a Class III medical device in the European Union and will serve to meet requirements under the new Medical Device Regulation (MDR).
SurgMark is an innovative company based in Hamburg, Germany, and specializing in medical technology solutions. The team of five doctors and scientists has already developed several products for surgery and wound healing. They have cleared Class III medical device processes with the FDA in the USA and with EMA in Europe. Management and shareholders have many years of industry experience and have already successfully founded and sold several start-ups in the field. Dr. Frank Schure, MD, gynecologist and co-founder of SurgMark, expresses his lifelong passion and joy about this success: "It is a dream coming true. I have been working in this field for decades, and we always wanted to bring this product to market. SchurSign® represents our commitment to innovation and patient care, and I am thrilled to see it making a positive impact for my patients in the future."